SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

SeraNovo B.V. has announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability. Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry.